Sujay Kango
Officer at Acceleron Pharma Inc (XLRN)
Sujay Kango has filed 16 insider reports with the SEC since February 2021, as director at Dianthus Therapeutics, Inc. /DE/ (DNTH), director at MEI Pharma, Inc. (LITS) and director at Infinity Pharmaceuticals, Inc. (INFI) and at 1 more company. Sujay Kango made no open-market purchases or sales in the last 12 months. The latest filing, on May 22, 2026, reports grant or award at Dianthus Therapeutics, Inc. /DE/ (DNTH).
- Filings
- 16
- Companies
- 4
- Bought on market
- None
- Sold on market
- $2.31M
Companies where Sujay Kango is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince March 2025 | $89.55 | May 22, 2026 | |||||
| Directorsince November 2021 | 0 | $0.8565 | Oct 12, 2023 | ||||
| Directorsince March 2022 | Mar 31, 2022 | ||||||
| Officer | 0 | $2.31M | Nov 22, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- May 21, 2026DNTHSEC Form 4 filed by Director Kango SujayForm 4Grant or award
- Mar 4, 2025DNTHSEC Form 4 filed by Director Kango SujayForm 4Grant or award
- Mar 4, 2025DNTHSujay Kango became an insiderForm 3New insider
- Sep 29, 2023LITSSEC Form 4 filed by Kango SujayForm 4Grant or award
- Jul 5, 2022LITSSEC Form 4 filed by Kango SujayForm 4Grant or award
- Mar 30, 2022INFISEC Form 4 filed by Kango SujayForm 4Grant or award
- Mar 30, 2022INFISujay Kango became an insiderForm 3New insider
- Nov 22, 2021LITSSEC Form 4 filed by Kango SujayForm 4Grant or award
- Nov 22, 2021LITSSEC Form 3: New insider Kango Sujay claimed no ownership of stock in the companyForm 3New insider
- Nov 19, 2021XLRNSEC Form 4: Kango Sujay closing all direct ownership in the company (for tax liability)Form 4Sale back to the companyTender of shares in a change of control
- Sep 27, 2021-$875KXLRNSEC Form 4: Kango Sujay exercised 5,000 shares at a strike of $40.61 and sold $875,000 worth of shares (5,000 units at $175.00) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Sep 21, 2021-$750KXLRNSEC Form 4: Kango Sujay sold $750,150 worth of Common Stock (5,000 units at $150.03) and exercised 5,000 units of Common Stock at a strike of $40.61Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Feb 12, 2021XLRNSEC Form 4: KANGO SUJAY covered exercise/tax liability with 887 units of Common Stock, decreasing direct ownership by 5% to 18,509 unitsForm 4Shares withheld for taxes or exercise price
- Mar 2, 2021-$680KXLRNSEC Form 4: Sujay Kango exercised 5,000 units of Common Stock at a strike of $40.61 and sold $680,059 worth of Common Stock (5,000 units at $136.01)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 29, 2021XLRNSEC Form 4: Sujay Kango was granted 5,409 units of Common Stock, increasing ownership by 39% to 19,396 unitsForm 4Grant or award
- Jan 4, 2021XLRNSEC Form 4: Sujay Kango exercised 10,000 units of Common Stock at a strike of $40.61, increasing ownership by 251% to 13,987 unitsForm 4Exercise or conversion of a derivative10b5-1 plan
Also sits on boards with
Officers and directors who share two or more companies with Sujay Kango.
Compare Sujay Kango with
- Sujay Kango vs Adam M Veness2 shared
- Sujay Kango vs Ryan Savitz1 shared
- Sujay Kango vs Edward Carr1 shared
- Sujay Kango vs Simrat Randhawa1 shared
- Sujay Kango vs Simon Read1 shared
- Sujay Kango vs Anne McGeorge1 shared
Other insiders at the same companies
- Ryan SavitzDNTH
- Edward CarrDNTH
- Simrat RandhawaDNTH
- Simon ReadDNTH
- Anne McGeorgeDNTH
- Marino GarciaDNTH
- James P FlynnLITS
- Steven J. RomanoDNTH
- Alison Frances LawtonDNTH
- Paula SoteropoulosDNTH
- Jonathan ViolinDNTH
- Justin J. FileLITS
- Alexander SchornsteinLITS
- Nicholas GloverLITS
- Frederick W DriscollLITS
Questions about Sujay Kango
- What is Sujay Kango's role at Acceleron Pharma Inc?
- Sujay Kango reports to the SEC as officer at Acceleron Pharma Inc (XLRN), according to the latest filing on November 22, 2021. Sujay Kango has also filed as director at Dianthus Therapeutics, Inc. /DE/ (DNTH), director at MEI Pharma, Inc. (LITS) and director at Infinity Pharmaceuticals, Inc. (INFI).
- Has Sujay Kango bought or sold stock recently?
- The most recent open-market sale was on September 27, 2021: sold 5,000 shares of Acceleron Pharma Inc (XLRN) for $875K at an average of $175.00.
- How do I get alerts when Sujay Kango files?
- Follow Sujay Kango on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Sujay Kango (SEC CIK 0001336503). Totals count each trade once, skipping amendments whose original is on file, from Feb 3, 2021 on. View on SEC EDGAR